Patents by Inventor Mark Mayhew

Mark Mayhew has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7618637
    Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heat shock protein in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious eases and cancers.
    Type: Grant
    Filed: June 13, 2002
    Date of Patent: November 17, 2009
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: James Rothman, F. Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takechi, Mark Mayhew
  • Publication number: 20080274128
    Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heat shock protein in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious eases and cancers.
    Type: Application
    Filed: June 13, 2002
    Publication date: November 6, 2008
    Inventors: James E. Rothman, F. Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takeuchi, Mark Mayhew
  • Publication number: 20050095667
    Abstract: The present invention relates to inhibitors of the KDEL receptor and therapeutic uses therefor. Certain proteins are functionally retained in the cellular endoplasmic reticulum via an interaction between a KDEL sequence and its receptor. According to the invention, blocking this interaction with a KDEL receptor inhibitor promotes the secretion of such proteins. In specific embodiments of the invention, KDEL receptor inhibitors may be used to promote the secretion of heat shock proteins, thereby rendering the secreted heat shock proteins more accessible to the immune system and improving the immune response to heat shock protein-associated antigens.
    Type: Application
    Filed: June 21, 2004
    Publication date: May 5, 2005
    Inventors: James Rothman, Mark Mayhew, Mee Hoe
  • Publication number: 20040235129
    Abstract: The present invention relates to inhibitors of the KDEL receptor and therapeutic uses therefor. Certain proteins are functionally retained in the cellular endoplasmic reticulum via an interaction between a KDEL sequence and its receptor. According to the invention, blocking this interaction with a KDEL receptor inhibitor promotes the secretion of such proteins. In specific embodiments of the invention, KDEL receptor inhibitors may be used to promote the secretion of heat shock proteins, thereby rendering the secreted heat shock proteins more accessible to the immune system and improving the immune response to heat shock protein-associated antigens.
    Type: Application
    Filed: June 25, 2004
    Publication date: November 25, 2004
    Inventors: James E. Rothman, Mark Mayhew, Mee H. Hoe
  • Publication number: 20040204361
    Abstract: The present invention relates to inhibitors of the KDEL receptor and therapeutic uses therefor. Certain proteins are functionally retained in the cellular endoplasmic reticulum via an interaction between a KDEL sequence and its receptor. According to the invention, blocking this interaction with a KDEL receptor inhibitor promotes the secretion of such proteins. In specific embodiments of the invention, KDEL receptor inhibitors may be used to promote the secretion of heat shock proteins, thereby rendering the secreted heat shock proteins more accessible to the immune system and improving the immune response to heat shock protein-associated antigens.
    Type: Application
    Filed: March 31, 2004
    Publication date: October 14, 2004
    Inventors: James E. Rothman, Mark Mayhew, Mee H. Hoe
  • Patent number: 6773707
    Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of a heat shock protein complexed to a hybrid antigen comprising an antigenic domain and a heat shock protein-binding domain. These methods and compositions may be used in the treatment of infectious diseases and cancers.
    Type: Grant
    Filed: August 10, 2000
    Date of Patent: August 10, 2004
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: James E. Rothman, Franz-Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takechi, Mark Mayhew
  • Patent number: 6761892
    Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of a heat shock protein complexed to a hybrid antigen comprising an antigenic domain and a heat shock protein-binding domain. These methods and compositions may be used in the treatment of infectious diseases and cancers.
    Type: Grant
    Filed: April 20, 2000
    Date of Patent: July 13, 2004
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: James E. Rothman, Franz-Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takechi, Mark Mayhew
  • Publication number: 20040127684
    Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heat shock protein in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers.
    Type: Application
    Filed: February 14, 2003
    Publication date: July 1, 2004
    Inventors: James E. Rothman, Franz-Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takechi, Mark Mayhew
  • Publication number: 20040101532
    Abstract: The present invention relates to immunotherapeutic compositions comprising an effective amount of a molecular chaperone such as a heat shock protein, preferably hsp70, non-covalently bound to one or more javelinized melanoma antigens and to methods of using the immunotherapeutic compositions to induce an immune response against melanoma in a subject. The immunotherapeutic composition may contain one or more heat shock proteins, such as one or more of hsp70, hsp90, gp96, BiP, and hsp40, and may contain one or more javelinized melanoma antigens.
    Type: Application
    Filed: January 2, 2004
    Publication date: May 27, 2004
    Inventors: Alan Houghton, Philip Livingston, Qais Al-Awqati, Mark Mayhew, Mee Hoe
  • Publication number: 20040097453
    Abstract: Administration of expressible polynucleolides encoding eukaryotic heat shock proteins to mammalian cells leads to the stimulation of an immune response to antigens present in those cells. This makes it possible to stimulate an immune response to target antigens, including target tumor antigens or antigens associated with an infectious disease, without having to isolate a unique antigen or antigen-associated heat shock protein for each target antigen by administering to a mammalian subject or to a group of mammalian cells containing the antigen, an expressible polynucleotide encoding a heat shock protein. The expressed heat shock protein may have the same structure as native heat shock proteins, or may have a modified form adapted to control the trafficking of the expressed heat shock protein within the cells.
    Type: Application
    Filed: March 11, 2003
    Publication date: May 20, 2004
    Inventors: James E. Rothman, F. Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takeuchi, Mark Mayhew
  • Publication number: 20040071725
    Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heat shock protein in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers.
    Type: Application
    Filed: February 14, 2003
    Publication date: April 15, 2004
    Inventors: James E. Rothman, Franz-Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takechi, Mark Mayhew
  • Publication number: 20040071723
    Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heat shock protein in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers.
    Type: Application
    Filed: February 14, 2003
    Publication date: April 15, 2004
    Inventors: James E. Rothman, Franz-Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takechi, Mark Mayhew
  • Publication number: 20040071720
    Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heat shock protein in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers.
    Type: Application
    Filed: February 14, 2003
    Publication date: April 15, 2004
    Inventors: James E. Rothman, Franz-Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takechi, Mark Mayhew
  • Publication number: 20040071722
    Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heat shock protein in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers.
    Type: Application
    Filed: February 14, 2003
    Publication date: April 15, 2004
    Inventors: James E. Rothman, Franz-Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takechi, Mark Mayhew
  • Publication number: 20040071721
    Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heat shock protein in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers.
    Type: Application
    Filed: February 14, 2003
    Publication date: April 15, 2004
    Inventors: James E. Rothman, Franz-Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takechi, Mark Mayhew
  • Publication number: 20040071724
    Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heat shock protein in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers.
    Type: Application
    Filed: February 14, 2003
    Publication date: April 15, 2004
    Inventors: James E. Rothman, Franz-Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takechi, Mark Mayhew
  • Patent number: 6719974
    Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of a heat shock protein complexed to a hybrid antigen comprising an antigenic domain and a heat shock protein-binding domain. These methods and compositions may be used in the treatment of infectious diseases and cancers.
    Type: Grant
    Filed: October 5, 2000
    Date of Patent: April 13, 2004
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: James E. Rothman, Franz Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takeuchi, Mark Mayhew
  • Publication number: 20040043419
    Abstract: The present invention relates to antigenic complexes, wherein an antigenic complex comprises a peptide or protein containing a plurality of epitopes non-covalently joined to a heat shock protein via a molecular tether referred to as a “javelin”. Such complexes do not require that each epitope Be defined, and may in certain embodiments, elicit both antibody and cell-mediated immune reactions. The complexes of the invention may be used to induce therapeutic immune responses directed toward the treatment or prevention of infectious diseases and malignancies.
    Type: Application
    Filed: August 13, 2003
    Publication date: March 4, 2004
    Inventors: James E. Rothman, Mee H. Hoe, Mark Mayhew
  • Patent number: 6673348
    Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of a heat shock protein complexed to a hybrid antigen comprising an antigenic domain and a heat shock protein-binding domain. These methods and compositions may be used in the treatment of infectious diseases and cancers.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: January 6, 2004
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: James E. Rothman, F. Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takeuchi, Mark Mayhew
  • Publication number: 20040002469
    Abstract: Administration of expressible polynucleotides encoding eukaryotic heat shock proteins to mammalian cells leads to the stimulation of an immune response to antigens present in those cells. This makes it possible to stimulate an immune response to target antigens, including target tumor antigens or antigens associated with an infectious disease, without having to isolate a unique antigen or antigen-associated heat shock protein for each target antigen by administering to a mammalian subject or to a group of mammalian cells containing the antigen, an expressible polynucleotide encoding a heat shock protein. The expressed heat shock protein may have the same structure as native heat shock proteins, or may have a modified form adapted to control the trafficking of the expressed heat shock protein within the cells.
    Type: Application
    Filed: September 10, 2002
    Publication date: January 1, 2004
    Inventors: James E. Rothman, F. Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takeuchi, Mark Mayhew